Tyr296
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr296  -  PLD2 (human)

Site Information
LILkCSSyRQARWWA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 10036102

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry (in vitro) ( 2 ) , mutation of modification site ( 1 , 2 , 3 ) , western blotting ( 2 )
Disease tissue studied:
breast cancer ( 2 )
Relevant cell line - cell type - tissue:
COS (fibroblast) ( 1 , 2 , 3 ) , MCF-7 (breast cell) ( 2 ) , MTLn3 (breast cell) ( 2 ) , RAW/LR5 (macrophage) ( 1 )

Upstream Regulation
Kinases, in vitro:
EGFR (human) ( 2 )

Downstream Regulation
Effects of modification on PLD2:
enzymatic activity, induced ( 2 , 3 ) , enzymatic activity, inhibited ( 2 )
Effects of modification on biological processes:
carcinogenesis, inhibited ( 2 ) , cell motility, altered ( 1 )

References 

1

Knapek K, et al. (2010) The molecular basis of phospholipase D2-induced chemotaxis: elucidation of differential pathways in macrophages and fibroblasts. Mol Cell Biol 30, 4492-506
20647543   Curated Info

2

Henkels KM, Peng HJ, Frondorf K, Gomez-Cambronero J (2010) A comprehensive model that explains the regulation of phospholipase D2 activity by phosphorylation-dephosphorylation. Mol Cell Biol 30, 2251-63
20176813   Curated Info

3

Henkels KM, et al. (2009) PLD2 has both enzymatic and cell proliferation-inducing capabilities, that are differentially regulated by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 389, 224-8
19715678   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.